These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17975794)

  • 1. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.
    Wesierska-Gadek J; Gueorguieva M; Kramer MP; Ranftler C; Sarg B; Lindner H
    J Cell Biochem; 2007 Dec; 102(6):1405-19. PubMed ID: 17975794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.
    Wesierska-Gadek J; Hajek SB; Sarg B; Wandl S; Walzi E; Lindner H
    Biochem Pharmacol; 2008 Dec; 76(11):1503-14. PubMed ID: 18761330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?
    Wandl S; Wesierska-Gadek J
    Ann N Y Acad Sci; 2009 Aug; 1171():242-9. PubMed ID: 19723061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
    Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
    Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    David-Pfeuty T
    Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
    Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
    Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
    Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
    Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.
    Trávnícek Z; Krystof V; Sipl M
    J Inorg Biochem; 2006 Feb; 100(2):214-25. PubMed ID: 16386795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
    Schang LM; Phillips J; Schaffer PA
    J Virol; 1998 Jul; 72(7):5626-37. PubMed ID: 9621021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of cyclin dependent protein kinase inhibitor olomoucine on the microenvironment of axonal regeneration after spinal cord injury: an experiment with rats].
    Tian DS; Wang W; Xu YL; Yu ZY; Xie MJ; Wang P; Zhang GB
    Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(13):901-5. PubMed ID: 16759516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
    Węsierska-Gądek J; Hackl S; Zulehner N; Maurer M; Komina O
    J Cell Biochem; 2011 Jan; 112(1):273-88. PubMed ID: 21080333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
    Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
    Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.
    Komina O; Wesierska-Gadek J
    Biochem Pharmacol; 2008 Dec; 76(11):1554-62. PubMed ID: 18761329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases.
    Vermeulen K; Strnad M; Krystof V; Havlícek L; Van der Aa A; Lenjou M; Nijs G; Rodrigus I; Stockman B; van Onckelen H; Van Bockstaele DR; Berneman ZN
    Leukemia; 2002 Mar; 16(3):299-305. PubMed ID: 11896531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle inhibitor enhances the resolution of HSV-1-induced proinflammatory response in murine microglial cells.
    Zhou Y; Guo YJ; Liu X; Mei YW
    Neurol Res; 2009 Nov; 31(9):910-6. PubMed ID: 19138471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.
    Knillová J; Bouchal J; Hlobilková A; Strnad M; Kolár Z
    Neoplasma; 2004; 51(5):358-67. PubMed ID: 15640940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK-inhibitor olomoucine inhibits cell death after exposure of cell lines to cytosine-arabinoside.
    Papazisis KT; Geromichalos GD; Kouretas D; Dimitriadis KA; Kortsaris AH
    Cancer Lett; 1999 Apr; 138(1-2):221-6. PubMed ID: 10378797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
    Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
    Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.